IP Library › Granted Patent US 11,091,527
Granted Patent B2
US 11,091,527 · App. 16/693,741 · Granted Aug 17, 2021

IL-2 muteins and uses thereof

Inventors: Nathan Higginson-Scott (Cambridge, MA); Joanne L. Viney (Cambridge, MA); Jyothsna Visweswaraiah (Cambridge, MA); Erik Robert Sampson (Cambridge, MA); Kevin Lewis Otipoby (Cambridge, MA)
Assignee: PANDION OPERATIONS, INC.
C07K14/55A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,091,527
App. No.
16/693,741
Granted
Aug 17, 2021
Kind
B2
Abstract

The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.

Claims (2)

1. A polypeptide consisting of the amino acid sequence of SEQ ID NO: 39.

2. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
CHANGE OF NAME Recorded Oct 13, 2020
From: PANDION THERAPEUTICS, INC.
To: PANDION OPERATIONS, INC.
Reel/Frame 054056/0903 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2020
From: HIGGINSON-SCOTT, NATHAN; VINEY, JOANNE L.; VISWESWARAIAH, JYOTHSNA; SAMPSON, ERIK ROBERT; OTIPOBY, KEVIN LEWIS
To: PANDION THERAPEUTICS, INC.
Reel/Frame 051742/0931 →
Continuity (5)
Continuation 16229133 · Dec 21, 2018
Continuation 16109897 · Aug 23, 2018
Provisional Application 62675972 · May 24, 2018
Provisional Application 62595357 · Dec 6, 2017
Related Publication 20200325202A1 · Oct 15, 2020
Cited By (1)
US 50,550